enVVeno Medical
NVNO
18 hedge funds and large institutions have $8.5M invested in enVVeno Medical in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more ownership
Funds ownership: 0.55% → 0.55% (+0%)
8% less capital invested
Capital invested by funds: $9.21M → $8.5M (-$716K)
10% less funds holding
Funds holding: 20 → 18 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$45.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.7K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$3.74K |
| 5 |
BlackRock
New York
|
+$3.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$67.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$56.5K |
| 3 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$55.1K |
| 4 |
Morgan Stanley
New York
|
-$8.04K |
| 5 |
EE
EWG Elevate
Roseville,
California
|
-$1.61K |
NVNO Hedge Fund Activity: Q1 2023 in Review
18 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q1 2023, worth a combined $8.5M — down 7.8% from $9.21M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NVNO and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was UBS O'Connor, adding an estimated $45.2K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $67.8K sold.
- 18 institutional investors held enVVeno Medical (NVNO) as of Q1 2023, down from 20 in Q4 2022.
- Funds reported $8.5M of enVVeno Medical stock for Q1 2023, down 7.8% quarter-over-quarter.
- 2 funds opened new enVVeno Medical positions in Q1 2023 and 4 closed out, a net change of -2 holders.
- The largest enVVeno Medical buyer in Q1 2023 was UBS O'Connor, an estimated $45.2K added.
- The largest enVVeno Medical seller in Q1 2023 was Two Sigma Advisers, an estimated $67.8K sold.
Based on aggregated 13F filings for Q1 2023.